tent5c Antibody

What is TENT5C and why is it important in immunological research?

TENT5C (also known as FAM46C) is a non-canonical cytoplasmic poly(A) polymerase upregulated in activated B cells that suppresses their proliferation . It specifically polyadenylates immunoglobulin mRNAs, regulating their half-life and consequently their steady-state levels . TENT5C is critically important in immunological research because it serves as a key regulator of humoral immunity by directly affecting antibody production and secretion . In human cells, the canonical TENT5C protein has 391 amino acid residues with a mass of 44.9 kDa and localizes to both the nucleus and cytoplasm . The enzyme catalyzes the transfer of adenosine molecules from ATP to mRNA poly(A) tails, enhancing mRNA stability and gene expression, making it an important target for studying B cell function and antibody production mechanisms .

What are the main experimental applications for TENT5C antibodies?

TENT5C antibodies are primarily used in several key experimental techniques for detecting and studying the protein's expression and function. Western blot is the most widely utilized application, allowing researchers to quantify TENT5C protein levels in cell lysates and tissue samples . Immunofluorescence assays employ TENT5C antibodies to visualize the subcellular localization of the protein, which is crucial for understanding its functional distribution between the nucleus and cytoplasm . Immunohistochemistry represents another common application, enabling detection of TENT5C in tissue sections to analyze expression patterns across different cell types and physiological conditions . These applications are essential for researchers investigating B cell development, plasma cell differentiation, and the role of TENT5C in antibody production and secretory pathway regulation .

How does TENT5C expression change during B cell activation and differentiation?

TENT5C expression shows a dynamic pattern during B cell activation and differentiation. It is significantly upregulated in activated B cells and is one of the top 50 upregulated genes in spleen and bone marrow plasma cells . The expression is particularly enhanced during plasma cell differentiation through specific innate signaling pathways . Notably, signaling from both surface Toll-like receptors (TLR1, 2, 4, 6) and intracellular receptors (TLR9) strongly upregulates TENT5C levels, promoting B cell lineage differentiation and enhancing immune response . This upregulation correlates with increased levels of PABPC1, which has been identified as a TENT5C interactor in multiple myeloma cells . In contrast, stimulation through the B cell receptor (BCR) and CD40 receptor (representing T cell-dependent activation) has limited effect on TENT5C expression, indicating that TENT5C upregulation is primarily driven by innate immune signaling pathways rather than adaptive immune mechanisms .

How can TENT5C antibodies be utilized to study the mechanism of immunoglobulin mRNA polyadenylation?

To effectively study TENT5C-mediated immunoglobulin mRNA polyadenylation, researchers should employ an integrated approach combining immunoprecipitation with RNA analysis. First, establish experimental and control groups using wild-type and TENT5C knockout/knockdown models . For immunoprecipitation, use high-specificity TENT5C antibodies optimized for RNA-protein complex isolation, and validate antibody specificity via Western blot using both wildtype and TENT5C-deficient samples . RNA isolated from immunoprecipitated complexes can then be analyzed using direct RNA sequencing methods, particularly Nanopore direct RNA-sequencing approaches that preserve poly(A) tail information . This allows for measurement of global poly(A) tail length distribution, which is critical for identifying TENT5C-specific targets . Complementary methodologies should include ribonucleoprotein immunoprecipitation followed by qRT-PCR targeting immunoglobulin transcripts to confirm direct interactions . For comprehensive analysis, perform comparative transcriptomics between wild-type and TENT5C-deficient B cells, focusing on immunoglobulin transcript stability and abundance, while also measuring protein output via ELISA or Western blot to correlate polyadenylation status with translation efficiency .

What are the technical considerations when using TENT5C antibodies to investigate differences between normal B cells and multiple myeloma cells?

When investigating differences between normal B cells and multiple myeloma (MM) cells using TENT5C antibodies, researchers must address several critical technical considerations. First, antibody selection is paramount—choose antibodies validated specifically for detecting both wild-type and mutant TENT5C variants, as MM frequently harbors TENT5C mutations or deletions . Sample preparation protocols must be optimized separately for normal B cells and MM cells due to their distinct proteome complexities; consider using phosphatase inhibitors to preserve post-translational modifications that may differ between normal and malignant cells . Control selection is crucial—include both positive controls (cells with known TENT5C expression) and negative controls (TENT5C knockout cells) alongside MM cells with confirmed TENT5C deletions or mutations . For quantitative comparison, implement dual-staining approaches in flow cytometry or immunofluorescence that simultaneously detect TENT5C and plasma cell markers (CD138) . When analyzing results, normalize TENT5C expression to appropriate housekeeping proteins that remain stable across both cell types, and consider chromosome 1p status as TENT5C gene location may affect expression levels in MM cells with chromosomal aberrations . Finally, functional assessment should incorporate measurements of ER stress markers, secretory pathway components, and proliferation markers, as TENT5C modulates the balance between secretory capacity and cell division in MM .

How do TENT5C antibodies help elucidate the mechanistic link between TLR signaling and antibody production in B cells?

TENT5C antibodies serve as crucial tools for elucidating the mechanistic connection between Toll-like receptor (TLR) signaling and antibody production in B cells. Researchers should design time-course experiments activating B cells with specific TLR agonists (particularly for TLR1/2, TLR4, TLR6/2, and TLR9) while monitoring TENT5C expression via Western blot or immunofluorescence using TENT5C-specific antibodies . To establish causality, comparative studies between wild-type and TENT5C knockout B cells responding to TLR stimulation should measure both TENT5C protein levels and downstream effects on immunoglobulin secretion . Chromatin immunoprecipitation (ChIP) experiments using antibodies against TLR-activated transcription factors can determine whether TENT5C upregulation occurs at the transcriptional level . Co-immunoprecipitation with TENT5C antibodies following TLR activation helps identify protein interaction partners in the signaling cascade, particularly with components of the polyadenylation machinery and MyD88-dependent pathway proteins, as mice lacking MyD88 (a key TLR signaling component) display similar phenotypes to TENT5C knockout mice . Subcellular fractionation followed by TENT5C immunoblotting can track protein localization changes following TLR activation, while ribosome profiling in conjunction with TENT5C immunoprecipitation helps determine how TLR signaling affects TENT5C's association with actively translating immunoglobulin mRNAs . Finally, in vivo validation using animal models immunized through TLR-dependent pathways, with subsequent immunohistochemical analysis using TENT5C antibodies, can confirm the relationship between TLR activation, TENT5C expression, and plasma cell development in lymphoid tissues .

What controls should be included when using TENT5C antibodies for Western blot analysis of B cell populations?

When designing Western blot experiments with TENT5C antibodies for B cell analysis, a comprehensive control strategy is essential. Primary controls must include positive controls (activated B cells or plasma cells with known high TENT5C expression) and negative controls (TENT5C knockout B cells or non-B cell lineages with minimal expression) . For loading controls, select proteins stable across B cell differentiation stages—α-tubulin is recommended as it remains consistent during B cell activation while traditional housekeeping proteins like GAPDH may fluctuate . Include a molecular weight ladder spanning 25-70 kDa to accurately identify the 44.9 kDa TENT5C protein . Time-course controls are critical when studying TENT5C dynamics during activation; collect samples at multiple timepoints (0, 24, 48, 72 hours) following various stimulation protocols (LPS, IL-4, TLR agonists) . Treatment-specific controls should compare B cells activated via different pathways (TLR vs. BCR stimulation) to demonstrate pathway specificity of TENT5C upregulation . For antibody validation, perform peptide competition assays where TENT5C antibody is pre-incubated with purified recombinant TENT5C protein before Western blotting to confirm binding specificity . Finally, include secreted protein controls by analyzing both cell lysates and culture supernatants to correlate TENT5C expression with immunoglobulin secretion, incorporating antibodies against immunoglobulin chains and other secreted proteins like IL-6 and GRP94 for comprehensive pathway analysis .

How should researchers optimize immunofluorescence protocols when using TENT5C antibodies to study subcellular localization?

Optimizing immunofluorescence protocols for TENT5C subcellular localization studies requires meticulous attention to fixation, permeabilization, and detection methods. Begin with fixation method optimization by comparing paraformaldehyde (4%, 10-15 minutes) versus methanol fixation (100%, -20°C, 10 minutes) to determine which best preserves TENT5C epitopes while maintaining cellular architecture . Permeabilization conditions must be carefully titrated; test graduated concentrations of Triton X-100 (0.1-0.5%) or saponin (0.1-0.3%) to enable antibody access to cytoplasmic and nuclear TENT5C without disrupting cellular compartments . For primary antibody incubation, optimize both concentration (typically 1:100-1:500) and duration (overnight at 4°C versus 1-2 hours at room temperature), validating specificity through parallel staining of TENT5C knockout cells . Incorporate co-staining with compartment-specific markers: anti-calnexin for endoplasmic reticulum, anti-DAPI for nucleus, and plasma cell markers like anti-CD138 to correlate TENT5C localization with cellular differentiation state . For signal amplification in cells with lower TENT5C expression, implement tyramide signal amplification or use high-sensitivity detection systems . Image acquisition should include z-stack collection (0.3-0.5μm intervals) for accurate three-dimensional localization, particularly important given TENT5C's dual nuclear/cytoplasmic distribution . Finally, perform quantitative analysis measuring co-localization coefficients between TENT5C and organelle markers, and correlate subcellular distribution patterns with functional states such as activation level, differentiation stage, and antibody secretion capacity using specialized image analysis software .

What experimental approaches can elucidate the functional relationship between TENT5C expression and antibody production?

To comprehensively investigate the functional relationship between TENT5C expression and antibody production, researchers should implement a multi-faceted experimental strategy. First, establish genetically modified B cell models with either TENT5C knockout (using CRISPR-Cas9) or inducible expression systems to enable controlled manipulation of TENT5C levels . Quantify antibody production through multiple complementary techniques: ELISA for secreted antibodies in culture supernatants, Western blots for both intracellular and secreted immunoglobulins, and flow cytometry to measure the percentage of IgG1 and IgA-positive cells following activation . For in vivo validation, compare serum protein electrophoresis profiles between wild-type and TENT5C knockout mice, focusing on gamma globulin fractions that contain antibodies, while maintaining other fractions (albumin, alpha, beta globulins) as internal controls . To establish mechanistic connections, perform polysome profiling with immunoglobulin-specific qRT-PCR to assess translation efficiency of antibody transcripts in the presence or absence of TENT5C . Implement mRNA stability assays using actinomycin D chase experiments to measure immunoglobulin transcript half-lives, correlating these measurements with their poly(A) tail lengths determined through direct RNA sequencing . Study the unfolded protein response (UPR) and ER stress pathways using TENT5C antibodies in conjunction with UPR markers, as TENT5C deficiency impairs the secretory pathway capacity . Finally, conduct rescue experiments by reintroducing either wild-type TENT5C or catalytically inactive mutants into knockout cells to confirm that polyadenylation activity directly mediates the observed effects on antibody production and secretion .

How can researchers address non-specific binding issues when using TENT5C antibodies in complex tissue samples?

When encountering non-specific binding with TENT5C antibodies in complex tissue samples, researchers should implement a systematic troubleshooting approach. Begin by optimizing blocking conditions—test different blocking agents including 5% BSA, 5-10% normal serum from the same species as the secondary antibody, commercial blocking buffers, or casein-based blockers, applying for 1-2 hours at room temperature . Antibody validation is critical; verify specificity using TENT5C knockout tissues as negative controls and perform peptide competition assays where pre-incubation of the antibody with recombinant TENT5C protein should abolish specific signals . Titrate primary antibody concentrations systematically (typically starting at 1:100 and diluting to 1:1000) to identify the optimal signal-to-noise ratio, and include additional washing steps (at least 3×15 minutes) with detergent-supplemented wash buffers (0.1-0.3% Tween-20 or Triton X-100) to remove unbound antibodies . Consider using monovalent Fab fragments instead of complete IgG antibodies when analyzing B cell-rich tissues to prevent endogenous immunoglobulin binding . For immunohistochemistry applications, implement antigen retrieval optimization comparing heat-induced epitope retrieval methods (citrate buffer pH 6.0 versus EDTA buffer pH 9.0) and enzymatic retrieval approaches . When performing multiplexed staining, adjust the detection order so TENT5C staining occurs before B cell markers to prevent cross-reactivity, and employ spectral unmixing during image analysis to separate overlapping fluorescence signals . Finally, consider tissue-specific autofluorescence quenching methods such as Sudan Black B treatment or commercial autofluorescence quenchers when performing immunofluorescence in tissues with high intrinsic fluorescence like spleen or bone marrow .

What methodological approaches can resolve contradictory findings between mRNA expression and protein detection of TENT5C in activated B cells?

When encountering discrepancies between TENT5C mRNA expression and protein detection in activated B cells, researchers should apply a systematic approach to identify the source of contradiction. First, implement time-course experiments with staggered sampling (2, 4, 8, 12, 24, 48, 72 hours post-activation) to account for temporal delays between transcription and translation, as TENT5C may exhibit asynchronous expression patterns during B cell activation . Verify RNA quality and processing by comparing multiple RNA extraction methods and implementing spike-in controls to ensure consistent recovery across samples, while also assessing multiple reference genes for normalization in qPCR beyond standard housekeeping genes, which may fluctuate during B cell activation . For protein analysis, expand detection methods beyond a single antibody by using multiple TENT5C antibodies targeting different epitopes, and employ alternative protein detection techniques such as targeted mass spectrometry to provide antibody-independent verification . Assess post-translational modifications and protein stability by treating samples with proteasome inhibitors (MG132) and performing pulse-chase experiments to determine if protein turnover rates differ across activation states . Investigate potential translational regulation by conducting polysome profiling to determine if TENT5C mRNA recruitment to ribosomes changes during activation despite consistent mRNA levels . Examine subcellular distribution through fractionation followed by Western blotting to detect potential sequestration of TENT5C in specific compartments that might affect antibody accessibility . Finally, implement single-cell analyses (RT-qPCR paired with immunofluorescence) to assess cell-to-cell variability, as population-level measurements may mask subpopulation-specific expression patterns during the heterogeneous process of B cell activation and differentiation .

How can researchers interpret changes in TENT5C localization during plasma cell differentiation in the context of antibody secretion capacity?

To properly interpret TENT5C localization changes during plasma cell differentiation and their relationship to antibody secretion, researchers must implement an integrated analytical framework. Begin with high-resolution confocal microscopy using co-immunofluorescence for TENT5C alongside markers for secretory organelles (calnexin for ER, GM130 for Golgi) and plasma cell maturation (CD138, IRF4, Blimp1) at defined differentiation stages . Quantify subcellular distribution using computational image analysis with overlap coefficients and distance measurements between TENT5C and organelle markers, tracking changes across the differentiation timeline . Correlate localization patterns with functional capacity by performing parallel analyses of antibody secretion rates (via ELISA) and intracellular immunoglobulin content (via flow cytometry) from the same cell populations used for localization studies . Implement electron microscopy with immunogold labeling for TENT5C to achieve nanoscale resolution of its association with ribosomes and ER membranes, critical structures in the antibody production machinery . Perform live-cell imaging using cells expressing fluorescently tagged TENT5C to track dynamic relocalization during active differentiation, particularly in response to ER stress induction or TLR stimulation . Integrate biochemical fractionation with TENT5C antibody detection across subcellular compartments, correlating the relative abundance in each fraction with markers of secretory pathway capacity like GRP94 and unfolded protein response activation . Finally, conduct functional intervention studies where TENT5C is artificially targeted to specific compartments using fusion constructs with localization signals, then measure the effect on antibody production to establish causality between localization patterns and secretory function . This multi-parameter approach enables researchers to distinguish between coincidental associations and mechanistically relevant localization changes during plasma cell differentiation.

How might TENT5C antibodies contribute to understanding resistance mechanisms in multiple myeloma immunotherapy?

TENT5C antibodies could significantly advance our understanding of resistance mechanisms in multiple myeloma (MM) immunotherapy through several innovative research applications. Recent findings have revealed a correlation between low TENT5C expression and resistance to anti-CD38 antibody (daratumumab) treatment, suggesting TENT5C's potential role in immunotherapy susceptibility . To investigate this connection, researchers should develop multiplexed immunohistochemistry panels combining TENT5C antibodies with immune checkpoint markers and spatial transcriptomics to characterize the tumor microenvironment in responding versus resistant patients . Flow cytometric analysis using TENT5C antibodies could stratify MM cells based on expression levels before and after treatment, correlating with therapy response metrics . Mechanistically, researchers should employ TENT5C antibodies in chromatin immunoprecipitation sequencing (ChIP-seq) experiments to identify potential epigenetic alterations affecting TENT5C expression in resistant cells . Co-immunoprecipitation studies with TENT5C antibodies could reveal protein interaction networks that differ between responsive and resistant cells, potentially identifying targetable pathways . For functional validation, TENT5C expression should be modulated in patient-derived xenograft models, followed by immunotherapy treatment and monitoring using TENT5C antibodies to track expression changes in remaining tumor cells . Single-cell analysis combining TENT5C antibody labeling with mass cytometry could characterize cellular heterogeneity within MM tumors, identifying subpopulations with intrinsic resistance properties . Finally, liquid biopsy approaches detecting TENT5C protein in circulating MM cells might serve as a non-invasive biomarker for predicting and monitoring immunotherapy response, potentially transforming clinical management of MM patients .

What novel methodological approaches could enhance the sensitivity and specificity of TENT5C detection in primary patient samples?

Enhancing TENT5C detection in primary patient samples requires innovative methodological approaches that overcome current technical limitations. Researchers should explore proximity ligation assays (PLA) that utilize paired TENT5C antibodies targeting different epitopes, generating amplifiable signals only when both antibodies bind in close proximity, dramatically increasing detection sensitivity while reducing background in heterogeneous patient samples . Another promising approach involves developing nano-immunoassays that combine microfluidic technology with TENT5C antibodies to analyze protein expression in minimal sample volumes—crucial for limited patient material . For enhanced specificity, implement antibody validation through orthogonal techniques including targeted mass spectrometry with selective reaction monitoring (SRM) to identify TENT5C-specific peptides independently of antibody binding . Develop CRISPR-epitope tagging in primary cells where endogenous TENT5C is tagged with small epitopes recognized by highly specific commercial antibodies, enabling reliable detection while maintaining physiological expression levels . For multiplexed analysis, employ cyclic immunofluorescence or mass cytometry with metal-conjugated TENT5C antibodies to simultaneously detect TENT5C alongside multiple B-cell differentiation markers in the same patient sample . Address tissue heterogeneity through spatial transcriptomics combined with TENT5C immunohistochemistry, correlating protein expression with transcriptional profiles at single-cell resolution . For longitudinal monitoring, develop slice culture systems from patient biopsies where live-cell imaging with fluorescently-labeled TENT5C antibody fragments can track dynamic expression changes in response to treatments . Finally, establish digital pathology workflows with machine learning algorithms trained on TENT5C immunohistochemistry patterns to automatically quantify expression levels and cellular distribution across large patient cohorts, standardizing interpretation and revealing subtle expression patterns not discernible through conventional analysis .

How can TENT5C antibodies be integrated into multi-omics approaches to understand the broader impact of polyadenylation on B cell function?

Integrating TENT5C antibodies into multi-omics frameworks provides unprecedented opportunities to comprehensively map polyadenylation effects on B cell function. Researchers should implement sequential immunoprecipitation using TENT5C antibodies followed by RNA sequencing (RIP-seq) to identify the complete repertoire of TENT5C-bound transcripts across different B cell activation stages, correlating binding patterns with poly(A) tail lengths measured through direct RNA Nanopore sequencing . Combine this with TENT5C ChIP-seq to determine if this predominantly cytoplasmic protein has chromatin-associated functions in certain cellular contexts, potentially revealing novel regulatory mechanisms . For spatial context, employ proximity labeling approaches where TENT5C is fused to enzymes like BioID or APEX2, enabling biotinylation of proximal proteins when expressed in B cells, followed by streptavidin pulldown and mass spectrometry to map the complete TENT5C interactome across different subcellular compartments . Develop integrated proteogenomic workflows where TENT5C immunoprecipitation is coupled with both RNA-seq and mass spectrometry, directly correlating TENT5C-bound transcripts with their translated proteins . Implement CRISPR screens targeting RNA processing factors in TENT5C-expressing versus knockout B cells, using TENT5C antibodies to monitor resulting changes in localization and function, thereby mapping genetic interactions within the polyadenylation regulatory network . For temporal dynamics, combine time-resolved transcriptomics and proteomics with TENT5C immunoprecipitation at defined activation timepoints to construct mathematical models predicting how TENT5C-mediated polyadenylation propagates through gene regulatory networks governing B cell differentiation . Finally, extend these approaches to single-cell resolution by developing computational pipelines that integrate single-cell TENT5C protein expression data from imaging mass cytometry with single-cell RNA-seq poly(A) tail length measurements, creating comprehensive maps of how polyadenylation heterogeneity contributes to functional diversity within B cell populations .

How do various TENT5C antibody clones differ in their detection capabilities across species and applications?

The performance of TENT5C antibody clones varies significantly across species and applications, requiring researchers to make informed selections based on experimental requirements. Monoclonal antibodies generally offer higher specificity but narrower species reactivity, with mouse-derived clones typically recognizing specific epitopes conserved between human and primate TENT5C but often failing to detect rodent orthologs due to sequence divergence at key epitope regions . Polyclonal antibodies provide broader epitope recognition and cross-species reactivity, with rabbit-derived polyclonals showing reliable detection across human, mouse, and rat samples, making them valuable for comparative studies . For application specificity, antibodies raised against N-terminal regions of TENT5C generally perform better in Western blot applications, while those targeting central domains typically excel in immunoprecipitation and chromatin immunoprecipitation applications . Conformation-specific antibodies recognizing three-dimensional epitopes are optimal for immunofluorescence and flow cytometry but may fail in applications involving denatured proteins . When detecting endogenous versus overexpressed TENT5C, sensitivity differences become apparent—high-affinity clones are essential for detecting low endogenous levels in resting B cells, while virtually any TENT5C antibody can detect the elevated levels in activated B cells or overexpression systems . Species cross-reactivity analysis reveals that approximately 60% of commercially available TENT5C antibodies detect human protein, 40% detect mouse orthologs, and only about 20% reliably detect both, reflecting the 87% amino acid sequence homology between these species . Application-specific performance metrics indicate that Western blot applications show the highest success rate (>85%) across antibody clones, followed by immunofluorescence (65-70%), immunohistochemistry (50-60%), and immunoprecipitation (40-45%), with flow cytometry showing the lowest consistent performance (30-35%) .

What technological advancements have improved the detection and analysis of TENT5C in complex biological samples?

Recent technological advances have significantly enhanced TENT5C detection and analysis in complex biological samples through innovations across multiple methodological domains. Next-generation antibody engineering has produced recombinant TENT5C antibodies with defined binding sites and consistent batch-to-batch reproducibility, overcoming traditional hybridoma variability issues . In detection system enhancement, super-resolution microscopy techniques like STORM and PALM now achieve 10-20nm resolution, enabling precise visualization of TENT5C co-localization with mRNA and polyadenylation machinery components previously unresolvable with conventional microscopy . For signal amplification, proximity extension assays have improved sensitivity by coupling TENT5C antibody binding with DNA polymerase-mediated signal amplification, allowing detection of femtomolar TENT5C concentrations in limited primary samples . Sample preparation advances include optimized tissue clearing protocols that maintain antibody epitopes while enabling deep tissue imaging, particularly beneficial for examining TENT5C distribution in intact lymphoid tissues . In multiplexed analysis, imaging mass cytometry now allows simultaneous detection of TENT5C alongside 40+ other proteins in single tissue sections using metal-tagged antibodies, providing unprecedented contextual data on TENT5C expression relative to the B cell differentiation landscape . Computational advances include machine learning algorithms that recognize subtle TENT5C expression patterns in immunohistochemistry images, revealing previously undetectable relationships between expression patterns and B cell functional states . For functional analysis, CRISPR-based precise genome editing now enables endogenous tagging of TENT5C without disrupting its regulation, allowing real-time monitoring of expression and localization in primary B cells . Finally, integrated single-cell technologies now combine protein detection via TENT5C antibodies with transcriptomic analysis in the same cells, directly correlating TENT5C protein levels with global gene expression patterns during B cell activation and differentiation, revolutionizing our understanding of TENT5C's regulatory networks .

What criteria should researchers use to validate TENT5C antibodies before experimental use?

Researchers must implement a comprehensive validation strategy for TENT5C antibodies to ensure experimental reliability. Begin with genetic knockout controls by testing antibodies on samples from TENT5C knockout models alongside wild-type tissues; a specific antibody will show signal only in wild-type samples . For epitope mapping, conduct peptide array analysis using overlapping TENT5C peptides to precisely identify binding regions, ensuring they are conserved across species if cross-reactivity is desired . Evaluate specificity through Western blot analysis, where a high-quality TENT5C antibody should produce a predominant band at 44.9 kDa in B cells with minimal non-specific binding . For orthogonal validation, compare protein detection with mRNA expression using qRT-PCR or RNA-seq across multiple B cell activation states, expecting concordance between transcript and protein levels . Test application versatility by validating each antibody across intended applications (Western blot, immunofluorescence, flow cytometry) as performance often varies between techniques . Assess performance in relevant biological contexts by comparing TENT5C detection in resting versus activated B cells, where levels should increase following activation with TLR agonists . For immunoprecipitation validation, perform mass spectrometry on immunoprecipitated proteins to confirm TENT5C enrichment and identify potential cross-reacting proteins . Establish reproducibility through inter-laboratory testing where possible, using standardized protocols to ensure consistent performance across different research settings . Finally, implement lot-to-lot validation by testing each new antibody lot against a reference lot to ensure consistent sensitivity and specificity, particularly important for longitudinal studies examining TENT5C expression in clinical samples or during extended experimental timelines .